Adicet Bio Inc (ACET) Stock: A Closer Look at the Analyst Ratings

NET Stock

Additionally, the 36-month beta value for ACET is 1.84. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”

The public float for ACET is 67.18M and currently, short sellers hold a 11.44% ratio of that float. The average trading volume of ACET on April 19, 2024 was 1.44M shares.

ACET) stock’s latest price update

Adicet Bio Inc (NASDAQ: ACET)’s stock price has decreased by -10.79 compared to its previous closing price of 2.27. However, the company has seen a -9.60% decrease in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-04 that Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

ACET’s Market Performance

ACET’s stock has fallen by -9.60% in the past week, with a monthly drop of -0.25% and a quarterly drop of -17.18%. The volatility ratio for the week is 6.55% while the volatility levels for the last 30 days are 6.54% for Adicet Bio Inc The simple moving average for the last 20 days is -9.44% for ACET stock, with a simple moving average of -1.66% for the last 200 days.

Analysts’ Opinion of ACET

JP Morgan gave a rating of “Neutral” to ACET, setting the target price at $6 in the report published on June 01st of the previous year.

ACET Trading at -16.91% from the 50-Day Moving Average

After a stumble in the market that brought ACET to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.00% of loss for the given period.

Volatility was left at 6.54%, however, over the last 30 days, the volatility rate increased by 6.55%, as shares sank -5.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.52% lower at present.

During the last 5 trading sessions, ACET fell by -9.60%, which changed the moving average for the period of 200-days by -25.82% in comparison to the 20-day moving average, which settled at $2.23. In addition, Adicet Bio Inc saw 7.14% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ACET starting from ORBIMED ADVISORS LLC, who purchase 3,125,000 shares at the price of $2.40 back on Jan 25 ’24. After this action, ORBIMED ADVISORS LLC now owns 7,526,359 shares of Adicet Bio Inc, valued at $7,500,000 using the latest closing price.

GORDON CARL L, the Director of Adicet Bio Inc, purchase 3,125,000 shares at $2.40 during a trade that took place back on Jan 25 ’24, which means that GORDON CARL L is holding 7,526,359 shares at $7,500,000 based on the most recent closing price.

Stock Fundamentals for ACET

The total capital return value is set at -0.81. Equity return is now at value -61.69, with -53.03 for asset returns.

Based on Adicet Bio Inc (ACET), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -4.48. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -6335.0.

Currently, EBITDA for the company is -126.48 million with net debt to EBITDA at 1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.41.


In conclusion, Adicet Bio Inc (ACET) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Most Popular

Related Posts